| Project/Area Number |
26860260
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Experimental pathology
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
Kurabe Nobuya 浜松医科大学, 医学部, 助教 (60466737)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 質量顕微鏡 / 胃癌 / フォスファチジルコリン / 抗がん剤 / iMScope / 大腸癌 / Akt |
|---|
| Outline of Final Research Achievements |
Currently, there are anti-cancer drugs available for gastric cancer (GC) treatment, while various side effects are intractable limitations for some patients. Here, to identify the anti-cancer drug candidate(s) for GC with no side effects, we performed an imaging mass spectrometry screening using a panel of non-neoplastic and neoplastic gastric tissue. Two species of phosphatidylcholine (PC), PC-34:2 and PC-36:4, were highly downregulated in GC. PC-34:2 and PC-36:4 suppressed the transformation of NIH3T3 cells driven by K-rasV12 and growth of 5 cell lines, while the growth of non-transformed NIH3T3 was not affected by PC-34:2. overexpression of LPCAT3 leads to growth suppression of MKN-28 cells. Considering that PCs have no toxic effect for human, these data indicate the usefulness of identified PC as potential anti-cancer drugs of GC.
|
